(Q24248011)

https://api.crossref.org/works/10.1002%2F14651858.CD001281

Twelve months, treatment with inhaled salmeterol in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

Inhaled salmeterol or oral theophylline in nocturnal asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

Cost comparison of beta 2-agonist bronchodilators used in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

Efficacy of salmeterol in the treatment of childhood asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

Inhibition by Ro 31-6930 of agonist and allergen induced bronchoconstriction in anaesthetised guinea-pigs and cats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD001281

1 reference

7 January 2021

The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Salmeterol versus theophylline in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

New combination therapies for asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Inhibitory effects of formoterol on platelet-activating factor induced eosinophil chemotaxis and degranulation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Pharmacokinetic optimisation of asthma treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021

A one-week dose-ranging study of inhaled salmeterol in children with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001281

7 January 2021